Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Cilia- and flagella-associated protein 263 (CFAP263), previously known as "coiled-coil domain containing 113" (CCDC113), is a protein predominantly localized to centriolar satellites and the ciliary basal body, where it contributes to the assembly and function of cilia[1][5]. It acts as a component of a protein complex that regulates ciliary beating by connecting structural elements critical for normal cilium motility and maintenance, including the radial spoke 3, inner dynein arm, and nexin-dynein regulatory complex[1][5]. Mutations in CFAP263 have been linked to human diseases such as retinitis pigmentosa and optic atrophy, indicating its importance in sensory and potentially neural tissues[1]. CFAP263 is not a typical receptor, enzyme, transporter, or common therapeutic target, but rather serves a structural role in cilia and flagella. There is some evidence suggesting a role in cancer, but its direct therapeutic targeting or use in biomarker applications remains unsupported by current evidence[7].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Cilia- and flagella-associated protein 263 (CFAP263).